RMC-6236 is named as a drug or biological intervention in 7 clinical trials in our USA, UK and China trial registers, 5 of which are recruiting. Lead sponsors include Revolution Medicines, Inc. (5), Amgen (1) and Tango Therapeutics, Inc. (1). Registered phases: Phase 1/2, Phase 1 and Phase 3. Conditions studied include PDAC; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) |
Phase 1/2 | Recruiting |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer |
Phase 1/2 | Recruiting |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (ClinicalTrials.gov ↗) Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma |
Phase 1/2 | Recruiting |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (ClinicalTrials.gov ↗) PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC |
Phase 1/2 | Recruiting |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) |
Phase 1 | Recruiting |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (ClinicalTrials.gov ↗) Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma |
Phase 3 | Active, closed |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (ClinicalTrials.gov ↗) Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PDAC | 3 |
| Non-small Cell Lung Cancer (NSCLC) | 2 |
| Colorectal Cancer (CRC) | 2 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | 2 |
| Advanced Solid Tumors | 2 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 2 |
| Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | 1 |
| NSCLC | 1 |
| RAS Mutation | 1 |
| Colorectal Cancer | 1 |
| CRC | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Pancreatic Cancer | 1 |
| Non-Small Cell Lung Cancer, NSCLC | 1 |
| KRAS, NRAS, HRAS-mutated NSCLC | 1 |
| KRAS G12C-mutated Solid Tumors, Lung Cancer | 1 |
| Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Revolution Medicines, Inc. | 5 |
| Amgen | 1 |
| Tango Therapeutics, Inc. | 1 |
| Register | RMC-6236 trials |
|---|---|
| Clinical trials in USA | 7 |
| Clinical trials in UK | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RMC-6236 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RMC-6236 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.